449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study

C Tron,F Lemaitre,C Locher,T Lecomte,C Tournigand,K Bouhier Leporrier,S Le Sourd,J-P Metges,D Tougeron,F Di Fiore,C Hervé,M Heran,Y Touchefeu,B.J-C Rousseau,A Hulin,A Lievre

doi:10.1016/j.annonc.2022.07.1870

449TiP Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study

C Tron, F Lemaitre + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1870

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: l'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier Universitaire de Tours, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire de Poitiers, Hôpital Saint-Antoine, Sorbonne Université, Centre d'Investigation Clinique de Nantes

#Therapeutic Drug Monitoring In Patients #Drug Monitoring In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In randomized clinical trials, regorafenib (REG) has demonstrated a benefit in overall survival (OS) in mCRC patients, but limiting toxicities make treatment discontinuation frequent. Managing the high inter-patient variability of REG pharmacokinetics (PK) should help prevent toxicity and prolong the anti-tumor effect. In the prospective TEXCAN study, a sum of plasma concentrations of REG and its two main active metabolites M2 and M5 (Csum) at Day15 of Cycle 1 within 2.5 - 5.5 mg/L was associated with an improved OS (1).

Full Text